NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
Clinical Trials
7 trialsNCT04487236 2025-08-11
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
Suzhou Zanrong Pharma Limited
Phase 1 Completed
NCT04421222 2025-02-28
EPI-7386
ESSA Pharmaceuticals
Phase 1 Terminated
NCT05561374 2024-11-29
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato, Inc.
Phase 1 Active not recruiting
NCT02278250 2023-03-16
First in Human Study of M4344 in Participants With Advanced Solid Tumors
EMD Serono
Phase 1 Completed
NCT01976741 2021-05-06
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
Phase 1 Completed
NCT01433731 2016-03-24
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
TetraLogic Pharmaceuticals
Phase 1 Completed